Dr. Cristóbal Orellana, Associate Physician at the Service of Rheumatology of the Parc Taulí Hospital (Sabadell, Barcelona) commented that biomarkers extracted from type II collagen, a type of collagen that can be found only in the cartilage, holds great promise for diagnosing osteoarthritis, and for monitoring its treatment.
Francisco J. Blanco García, rheumatologist of the A Coruña University Hospital Complex will present the “Arthrosischip” Project, which aims to predict the development of osteoarthritis. Bioibérica is the only Spanish pharmaceutical company that will be present at OARSI 2011
They will sponsor two symposiums, one on personalized medicine, and another on the treatment of chronic osteoarthritis
The city of Barcelona, in collaboration with Bioibérica, will host OARSI2012.
BIOIBERICA has been present at the EULAR Congress 2011, the most important European event on rheumatic diseases. This year' edition has been held in London, UK.
Professor Jean-Pierre Pelletier from Montreal, Canada, presented the results of a clinical trial that confirm the disease-modifying effects of chondroitin sulphate. These results have also been presented in an article published in the June issue of Annals of the Rheumatic Diseases. Spanish rheumatologist Francisco J. Blanco, from the Corunna hospital, confirmed the efficacy of the combination of chondroitin sulphate and glucosamine to combat osteoarthritis.
Dr. Virginia Byers Kraus from Durham, USA, determined that osteoarthritis has an important inflammatory aspect, thus redefining our concepts about that disease
The Arthrosischip is a new diagnostic tool. Based upon the genetic information of every individual, it could predict the future development of knee osteoarthritis
Rheumatologist Dr. Francisco Blanco Garcia presented in the XXXVII National Congress of the Spanish Society of Rheumatology (SER 2011), held in Malaga, the research project that is working on the development of that tool. Thirty-two research centres from all over Spain are participating in this project
* This website is not intended to report adverse events related to Bioiberica's products. If you would like to report a suspected adverse reaction, please contact the Department of Pharmacovigilance Bioiberica.